• Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Bausch Health Companies Inc.

Headquarters: Laval, QC, Canada
Website: https://www.bauschhealth.com...
Year Founded: 1960
Status: Public
Industry Sector: HealthTechnology
CEO: Thomas J. Appio
Number Of Employees: 20,700
Enterprise Value: $24,568,272,146
PE Ratio: -42.3
Exchange/Ticker 1: NYSE:BHC
Exchange/Ticker 2: TSX:BHC
Latest Market Cap: $1,725,798,400

BioCentury | Jan 18, 2025
Politics, Policy & Law

Diabetes, cancer drugs dominate CMS’s new price negotiation list

Ozempic tops list of 15 drugs whose negotiated prices will take effect in 2027
Read More
BioCentury | Jul 8, 2022
Finance

2Q22 Wrap: it could be worse

Bleeding continued in biopharma in second quarter, with median market caps down in all tiers
Read More
BioCentury | May 9, 2022
Management Tracks

CEO Siegall takes leave of absence at Seagen

Plus Martin stepping down as CEO of ADC and updates from
Read More
BioCentury | May 7, 2022
Finance

May 6 Quick Takes: PepGen prices bumped up IPO below range

Plus Demand light for Bausch + Lomb IPO, and updates from Myovant-Pfizer, Novartis and more
Read More
BioCentury | Mar 9, 2022
Management Tracks

Oxford spinout MiroBio adds Keswani as CMO, promotes Murray to CSO

Plus updates from Centessa, Teon, AnchorDx, Pillar and more
Read More
BioCentury | Oct 27, 2021
Emerging Company Profile

MoonLake: IL-17 advances in a Nanobody package 

Awaiting a SPAC, the Swiss company thinks it can bring more efficacy, safety to IL-17-driven diseases
Read More
BioCentury | Oct 26, 2021
Product Development

Oct. 25 Quick Takes: FDA approves Bausch + Lomb’s Xipere 

Plus AstraZeneca, AnaptysBio, Novartis, Sanofi and more
Read More
BioCentury | Oct 1, 2021
Regulation

At least 14 PDUFA dates on deck in October: Data Byte

Seven for new drugs and seven for label extensions
Read More
BioCentury | Sep 1, 2021
Management Tracks

Zaks joins board at Teva

Jogerst named CBO at Rubius, plus updates from Telix, Talis, Ziopharm, Pyxis and more
Read More
BioCentury | Jul 2, 2021
Distillery Therapeutics

SHH, YAP1 inhibition for genetic, acquired heterotopic ossification

DISEASE CATEGORY: Musculoskeletal
INDICATION: Bone repair Targeting the hedgehog ligand SHH or YAP1, which drives SHH expression, could treat both genetic and acquired forms of heterotopic
Read More
Items per page:
1 - 10 of 73
Help Center
Username
Request Training
Submit Data Correction
Ask a Question
Elevio by Dixa